Side-by-side · Research reference
CartalaxvsFOXO4-DRI
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED10/32 cited
BAnimal-StrongHUMAN-REVIEWED12/45 cited
Cartalax
Bioregulator Peptide · Khavinson School
SQ · Protocol Unspecified
FOXO4-DRI
Senolytic Peptide · D-Retro-Inverso
SQ · Animal models only
01Mechanism of Action
Parameter
Cartalax
FOXO4-DRI
Primary target
Mesenchymal stem cells (MSCs) undergoing chondrogenic differentiationLinkova 2023
FOXO4-p53 protein complex in senescent cellsBourgeois 2025Tripathi 2021
Pathway
Modulation of WNT, ERK-p38, and Smad 1/5/8 signaling pathwaysLinkova 2023
FOXO4-DRI binds disordered p53 transactivation domain → displaces FOXO4 → nuclear p53 exclusion → p53-mediated apoptosis in senescent cells
Downstream effect
Upregulation of chondrogenic genes (COL2, SOX9, ACAN); increased bone mineral density; osteoprotective effects in ovariectomy-induced osteoporosisLinkova 2023Povorozniuk 2007
Selective apoptosis of senescent cells; clearance restores tissue homeostasisTripathi 2021Alameen 2026
Feedback intact?
—
—
Origin
Derived from cartilaginous tissue extracts (Khavinson bioregulator methodology)Povorozniuk 2007
D-retro-inverso modification — inverted amino acid sequence, D-amino acids for protease resistance
Antibody development
—
—
02Dosage Protocols
Parameter
Cartalax
FOXO4-DRI
Animal model dose
Unspecified (cartilaginous tissue extract protocol)
Rat study; extract preparation details not indexed in available abstracts.
—
Human dosing
Not established in PubMed-indexed literature
Russian-tradition protocols exist but lack peer-reviewed Western validation.
—
Evidence basis
Animal mechanistic studies only
Animal / mechanistic
Animal dose (mouse)
—
5 mg/kg
SQ injection, aged mouse model (testosterone restoration).
Frequency (animal)
—
Variable — single or intermittent dosing
Protocol-dependent; no standardised regimen.
Human equivalent (theoretical)
—
~0.4 mg/kg (28 mg / 70 kg adult)
Extrapolated using allometric scaling; no clinical validation.
Route
—
SQ (animal)
No human route established.
Duration
—
Weeks to months (animal studies)
Senescent cell clearance observed within weeks.
Clinical status
—
No human trials completed
03Metabolic / Fat Loss Evidence
Parameter
Cartalax
FOXO4-DRI
Fat loss evidence
None — primary target is cartilage and bone tissue, not adipose
—
04Side Effects & Safety
Parameter
Cartalax
FOXO4-DRI
Documented adverse effects
None reported in indexed animal studies
—
Human safety data
Not available in PubMed-indexed literature
—
Pulmonary hypertension risk
—
Senescent cell elimination promoted PH development/progression in rodent modelsBorn 2023
Context-dependent toxicity
—
Beneficial effects may be tissue/context-specific; elimination not universally protectiveBorn 2023
Off-target apoptosis
—
Theoretical risk of non-senescent cell apoptosis (selectivity not absolute)
Immune perturbation
—
Senescent cells contribute to immune surveillance; clearance effects unknown
Human safety unknown
—
No clinical trials — toxicity profile in humans not established
Absolute Contraindications
Cartalax
- ·Unknown due to lack of human clinical trial data
FOXO4-DRI
- ·Pulmonary hypertension or vascular disease (preclinical evidence of harm)Born 2023
- ·Pregnancy / lactation (no safety data)
Relative Contraindications
Cartalax
- ·Active malignancy (theoretical; peptide bioregulators may influence cell proliferation pathways)
FOXO4-DRI
- ·Active malignancy (senescence as tumour suppressor mechanism)
- ·Wound healing / tissue repair (senescent cells involved in fibrosis resolution)
05Administration Protocol
Parameter
Cartalax
FOXO4-DRI
1. Route
Subcutaneous injection typical for Khavinson bioregulators; specific protocols not detailed in indexed literature.
Subcutaneous injection used in rodent models. No human administration protocol exists.
2. Frequency
Russian-tradition protocols often employ 10-day cycles; precise frequency unspecified in available abstracts.
Typically reconstituted in sterile saline or PBS for animal experiments. Stability data limited.
3. Storage
Lyophilised peptide bioregulators typically stored at 2–8 °C, light-protected. Reconstitution details not indexed.
Variable — single bolus or intermittent dosing over weeks. No standardised human protocol.
4. Clinical development status
—
No registered human trials. Commercialisation by Cleara Biotech (Netherlands) in development phase.
5. Safety monitoring (proposed)
—
Would require cardiovascular assessment, pulmonary function, immune panel, tumour surveillance if human trials proceed.